Skip to main content
Skip to main content
NARI logo

Inari Medical, Inc. (NARI) Stock Analysis

Educational signal · not a buy or sell recommendation · How to read this

DELISTED 2025

What happened to Inari Medical, Inc. (NARI) stock?

Inari Medical, Inc. (NARI) no longer trades on public markets. It was delisted in February 2025. The figures below are historical and are not a current quote.

MCap: $4.68B| Vol: 2.36M|

Market cap $4.68B is the value of all shares combined.

Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Inari Medical, Inc. (NARI). Inari Medical, Inc. is a medical device company focused on developing and commercializing innovative solutions for the treatment of venous diseases.

Last analyzed: Sep 10, 2026

Inari Medical, Inc. is a medical device company focused on developing and commercializing innovative solutions for the treatment of venous diseases. Their key products, ClotTriever and FlowTriever, address large clot removal in deep vein thrombosis and pulmonary embolism, respectively.

Analyst Coverage for NARI: NARI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NARI against sector peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.

Watch the NARI film Every key number, told as a short cinematic story — just press play. ~2 min
Council Score · Weighted Average of 3 Disciplines
Split View 52/100 · B

NARI: 1/2 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.

How is this calculated? →
Legends Council · 5 Legends + Moon AI

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated)Ray Dalio
Favorable read
Englander-style lens (simulated)Izzy Englander
Favorable read
Klarman-style lens (simulated)Seth Klarman
Unfavorable read
Moon AI lens (model)
Favorable read
Munger's Mindset · Balance Sheet & Valuation
Financial Health
Neutral
Margin of Safety
Overvalued
Council Score · Weighted Average of 3 Disciplines · See tabs for details →
The lenses are modelled on the published principles of the investors named. We are not affiliated with them, they have not endorsed this, and it is not their opinion of this stock.

Inari Medical, Inc. Company Overview

Data Provenance | Financial Data Quantitative Analysis

Research confidence

Low 0/100

Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.

  • Scoring coverage unknown
  • Price 26 days old
  • No filing on record
  • No analyst coverage

Company Profile: Inari Medical, Inc.

Listed on a major U.S. exchange, Inari Medical, Inc. is a publicly traded company. With a market capitalization of $4.68B, it is classified as a mid-cap stock, reflecting its relative size within the broader equity market.

NARI Current Price & Trading Activity

NARI is currently trading at $79.97, with a daily change of +0.00 (+0.00%). The stock has a trading volume of 2.36M shares, which provides insight into market interest and liquidity for this security. Based on the current price and market capitalization, NARI has approximately 59 million shares outstanding.

Analyst Coverage for NARI

NARI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model scores NARI on quantitative fundamentals — growth, financial health, valuation, and momentum — relative to sector peers and assigns a neutral fundamental signal based on the underlying data. Investors monitoring NARI should weigh peer-relative metrics and sector momentum more heavily until institutional coverage emerges.

Data sourced from Financial Modeling Prep, Yahoo Finance and SEC EDGAR. This content is generated from market data and is not financial advice. Past performance does not guarantee future results.

NARI Latest News

No recent news available for NARI.

Investor Questions: NARI Stock

What happened to Inari Medical, Inc. (NARI) stock?

Inari Medical, Inc. (NARI) no longer trades on public markets. It was delisted in February 2025. The figures below are historical and are not a current quote.

Can I still buy NARI shares?

No. NARI stopped trading on public markets in February 2025, so the shares are not available through a broker. Anything you see quoted for NARI elsewhere is historical data, not a live market.

Are the figures on this page current?

No. Every number here is the last value recorded before NARI stopped trading. Nothing on this page updates, and none of it is a current quote.

Why does this page still exist?

Because people still search for what happened to Inari Medical, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

More Stocks We Cover